Nov 10, 2022 4:05 pm EST Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 20, 2022 8:00 am EDT Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia
Sep 30, 2022 8:00 am EDT Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.
Jul 27, 2022 8:00 am EDT Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member